» Articles » PMID: 32337895

Evaluation of the Immune Response Against ; in Infused BALB/c Mice by PcDNA3.1(+)-

Overview
Specialty General Medicine
Date 2020 Apr 28
PMID 32337895
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of the present study was to produce a pcDNA3.1(+)-ureA recombinant vector and evaluate the capacity of this vector to stimulate the immune response against H. pylori infection in infused BALB/c mice.

Materials And Methods: The pcDNA3.1(+)-ureA construct was prepared and transformed into E. coli, successfully. The animals we used in the study were allotted into three groups for infusion of 1) recombinant plasmid, 2) pcDNA3.1(+)-ureA + nanoparticles, and 3) pcDNA3.1(+). Blood and tissue specimens from each group of mice were collected at days 15, 30, and 45 after the last infusion and the expression levels of cytokines such as TGF-β1, IL-4, and IFNγ genes comparing to GAPDH as well as the expression of ureA in the mice’s thigh muscle were evaluated.

Results: The genes expression analysis showed that the IL4 expression significantly decreased (p<0.001) but IFNγ and TGF-β1 expression increased in the blood of infused mice (p<0.001). Also, the urea expression level in pcDNA3.1(+)-urea and pcDNA3.1(+)-ureA+ nanoparticle 15, 30, and 45 days after the last infusion was significantly different (p<0.001) and its expressions at days 15 and 30 were significantly different (p<0.001), but 45 days after the last infusion it was not significantly different (p>0.05).

Conclusion: The pcDNA3.1(+)-ureA recombinant vector with or without chitosan nanoparticles can stimulate the immune response in animal models against H. pylori infection. Also, after combining the recombinant vector with nanoparticles we observed a better immune response was observed. In future studies this recombinant construct can be used as a biomarker and therapeutic approaches in eukaryotic systems.

Citing Articles

Pivotal role of virulence genes in pathogenicity and vaccine development.

Elbehiry A, Marzouk E, Abalkhail A, Sindi W, Alzahrani Y, Alhifani S Front Med (Lausanne). 2025; 11():1523991.

PMID: 39850097 PMC: 11756510. DOI: 10.3389/fmed.2024.1523991.


How Long Will It Take to Launch an Effective Vaccine for Humans?.

Li S, Zhao W, Xia L, Kong L, Yang L Infect Drug Resist. 2023; 16:3787-3805.

PMID: 37342435 PMC: 10278649. DOI: 10.2147/IDR.S412361.


In Peripheral Blood Mononuclear Cells Induces the Secretion of Soluble and Exosomal Cytokines Related to Carcinogenesis.

Atrisco-Morales J, Ramirez M, Castanon-Sanchez C, Roman-Roman A, Roman-Fernandez I, Martinez-Carrillo D Int J Mol Sci. 2022; 23(15).

PMID: 35955936 PMC: 9368997. DOI: 10.3390/ijms23158801.